CL
CellaVision AB (publ)
CLVSF · OTC
$14.00 +0.00% (+$0.00)
Market Cap 3.28B kr
P/E Ratio 25.50x
Div. Yield 2.12%
ROE 14.59%
Bulios Fair Price
$8.6
38.6% downside
Current Price
$14
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CLVSF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
43 /100
Fair P/E 25.50x
EV/EBITDA 16.82x
P/S 4.45x
Growth
66 /100
Stable EPS growth 8.98%
Rev. growth 5.88%
FCF growth 18.97%
Profitability
93 /100
Strong Gross margin 68.71%
Net margin 17.47%
Op. margin 22.24%
Quality
71 /100
Excellent ROIC 12.74%
ROE 14.59%
ROA 11.38%
Debt
100 /100
Low Debt/Equity 0.06x
Current ratio 3.31x
Int. coverage 68.64x
Stability
100 /100
Stable Beta 0.87x
Rev. volatility 0.92%
EPS volatility 1.02%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CLVSF
Online
Sector
Healthcare
Industry
Medical - Devices
CEO
Steve Ferguson
Employees
251
Headquarters
Lund
Upcoming events
28 OCT
Earnings
Upcoming earnings report